Your browser is no longer supported. Please, upgrade your browser.
Settings
ATXI Avenue Therapeutics, Inc. daily Stock Chart
ATXI [NASD]
Avenue Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.91 Insider Own0.60% Shs Outstand16.32M Perf Week-2.07%
Market Cap92.86M Forward P/E- EPS next Y-0.95 Insider Trans39.05% Shs Float6.37M Perf Month21.06%
Income-22.40M PEG- EPS next Q-0.48 Inst Own7.10% Short Float0.23% Perf Quarter3.45%
Sales- P/S- EPS this Y-13.90% Inst Trans68.49% Short Ratio0.25 Perf Half Y7.77%
Book/sh1.48 P/B3.84 EPS next Y44.40% ROA-183.20% Target Price12.00 Perf Year44.42%
Cash/sh- P/C- EPS next 5Y- ROE-326.00% 52W Range2.08 - 7.98 Perf YTD5.37%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.32% Beta-
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low171.10% ATR0.39
Employees6 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)53.33 Volatility5.76% 7.58%
OptionableNo Debt/Eq0.00 EPS Q/Q20.20% Profit Margin- Rel Volume0.33 Prev Close5.69
ShortableYes LT Debt/Eq0.00 EarningsMay 09 Payout- Avg Volume59.62K Price5.64
Recom1.30 SMA200.77% SMA5012.07% SMA20017.51% Volume19,867 Change-0.88%
Jun-07-19 01:51PM  3 Foolproof Strategies To Minimize Risk Benzinga
Jun-03-19 12:05PM  Avenue Therapeutics Trades Higher After Phase 3 Success Benzinga +15.00%
07:00AM  Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain GlobeNewswire
May-13-19 07:30AM  Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights GlobeNewswire
Apr-30-19 07:30AM  Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors GlobeNewswire
Mar-12-19 07:30AM  Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Feb-11-19 07:30AM  Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary) GlobeNewswire
Jan-28-19 10:05AM  ATXI: How Much Are CVRs Worth? Zacks Small Cap Research
Jan-19-19 06:45PM  Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of the Securities of Avenue Therapeutics, Inc. (NasdaqCM: ATXI) GlobeNewswire
Dec-19-18 08:00AM  Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain GlobeNewswire -5.14%
Dec-12-18 08:00PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI PR Newswire
Dec-03-18 09:15AM  ATXI: InvaGen Acquisition Spices Up Quarterly Report Zacks Small Cap Research
Nov-21-18 07:45AM  Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-14-18 04:30PM  Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire +7.78%
Nov-13-18 12:00PM  ATXI: InvaGen Capital Raise & Acquisition Zacks Small Cap Research +11.30%
06:30AM  InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S. GlobeNewswire
Aug-27-18 01:45PM  ATXI: Second Quarter 2018 Results Zacks Small Cap Research
Aug-14-18 07:30AM  Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire -5.32%
Aug-02-18 10:29AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters -17.26%
09:40AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters
Jun-19-18 08:30AM  Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference GlobeNewswire
Jun-12-18 09:30AM  ATXI: KOL Call with Drs. Singla and Minkowitz on IV Tramadol Zacks Small Cap Research -6.09%
Jun-06-18 08:30AM  Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain GlobeNewswire
May-23-18 07:25AM  Blog Exposure - Avenue Therapeutics Reported Positive Results from Pivotal Phase-3 Trial of IV Tramadol ACCESSWIRE
May-21-18 08:59AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain GlobeNewswire
May-14-18 10:30AM  ATXI: 1Q:18 Update Confirms Timeline Zacks Small Cap Research
May-03-18 07:30AM  Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire -5.06%
Apr-10-18 01:20PM  ATXI: No Pain? We See a Gain; Developing Tramadol Zacks Small Cap Research
Mar-28-18 08:00AM  Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol GlobeNewswire
Mar-05-18 08:00AM  Avenue Therapeutics to Present at March Investor Conferences GlobeNewswire
Mar-01-18 07:30AM  Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
Feb-09-18 10:00AM  Avenue Therapeutics, Inc. (Nasdaq: ATXI) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Feb-06-18 08:30AM  Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor Conference GlobeNewswire
Jan-02-18 08:00AM  Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain GlobeNewswire +5.80%
Nov-09-17 07:30AM  Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights GlobeNewswire +5.79%
Sep-27-17 08:00AM  Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain GlobeNewswire
Aug-15-17 08:00AM  Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer) GlobeNewswire -7.09%
Aug-11-17 07:30AM  Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
Jul-03-17 01:02PM  Here's the Latest on Four New Biotech IPOs TheStreet.com
08:00AM  Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics GlobeNewswire
Jul-02-17 09:50AM  IPOs This Week: A Single Offering on Tap After 8 IPOs Last Week 24/7 Wall St.
Jun-30-17 11:30AM  Avenue Therapeutics Completes Initial Public Offering GlobeNewswire
Jun-28-17 08:20AM  Blue Apron Pricing To Heat Up Crazy IPO Week: Investing Action Plan Investor's Business Daily
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Herskowitz NeilDirectorApr 15Buy4.521,0004,52094,663Apr 15 04:33 PM
Herskowitz NeilDirectorMar 29Buy5.111,4007,15493,663Mar 29 04:33 PM
Herskowitz NeilDirectorMar 28Buy5.116003,06692,263Mar 29 04:33 PM
Herskowitz NeilDirectorFeb 25Buy5.465,00027,30091,663Feb 25 04:13 PM
Herskowitz NeilDirectorFeb 05Buy5.771,85010,67586,663Feb 06 04:31 PM
Herskowitz NeilDirectorFeb 04Buy5.917,00041,37084,813Feb 06 04:31 PM
Herskowitz NeilDirectorJan 30Buy5.916503,84277,813Feb 01 12:48 PM
Herskowitz NeilDirectorJan 29Buy5.918,55350,54877,163Jan 30 04:18 PM
Herskowitz NeilDirectorJan 28Buy5.841,4478,45068,610Jan 30 04:18 PM
Paley JeffreyDirectorDec 10Buy4.765,00023,80079,663Dec 12 01:15 PM
Paley JeffreyDirectorDec 03Buy5.4810,00054,75474,663Dec 12 01:15 PM